Breaking News: BioAtla Inc. Launches Exciting Direct Offering to Propel Two Mid-Stage Clinical Programs Towards Major Milestones!
Description
SAN DIEGO, Dec. 20, 2024 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company (“BioAtla” or the “Company”) focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into definitive agreements with certain institutional investors for the issuance and sale of 9,679,158 shares of its common stock in a registered direct offering. Each share of common stock offered was sold with a warrant to purchase one share of common stock at an exercise price of $1.19 per share. Each warrant will be exercisable beginning six months after issuance and will expire 5.5 years from the date of issuance. The combined offering price per share of common stock and accompanying warrant is $0.9520. The closing of the offering is expected to occur on or about December 20, 2024, subject to the satisfaction of customary closing conditions.
What This Means for Me
As a potential investor, this direct offering by BioAtla Inc. presents an opportunity to participate in the growth and development of innovative biotechnology solutions that can potentially revolutionize cancer treatment. By investing in this offering, you could be supporting the advancement of two mid-stage clinical programs that are aimed at achieving significant milestones in the treatment of solid tumors. Additionally, the inclusion of warrants in the offering provides the potential for increased returns on your investment once they become exercisable.
How This Will Impact the World
The launch of this direct offering by BioAtla Inc. signifies a significant step forward in the field of biotechnology and cancer treatment. The company’s focus on developing Conditionally Active Biologic (CAB) antibody therapeutics has the potential to bring about groundbreaking advancements in the way solid tumors are treated. By providing funding for these programs, investors are contributing to the advancement of medical science and potentially improving outcomes for patients worldwide who are battling cancer.
Conclusion
In conclusion, BioAtla Inc.’s direct offering is not just a financial opportunity but also a chance to support innovative research that could have a lasting impact on the field of oncology. By investing in this offering, you are not only investing in the future of the company but also in the potential for improved treatment options for cancer patients. It’s a step towards major milestones in the fight against solid tumors, and your participation can make a difference both personally and globally.
